02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
20:41 , Nov 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer; cancer Patient sample, cell culture and mouse studies suggest promoting H1.0 expression could help treat breast and other cancers. In patients with 19 types of cancer, low tumors levels of H1.0 correlated...
07:00 , Apr 11, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer H3 histone family 3A (H3.3A; H3F3A); histone cluster 1 H3b (HIST1H3B); polycomb repressive complex 2 (PRC2) In vitro and...
07:00 , Sep 30, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Nerve damage Histone cluster 1 H1A (HIST1A1; HIST1) A study in mice suggests that HIST1 may help treat nerve damage. In a mouse model of...
08:00 , Nov 19, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Sepsis Histone cluster 4, H4 (HIST4H4) Studies in cell culture and in mice suggest that blocking HIST4H4 could help treat sepsis. Mice injected with...